Annual monitoring of side effects of administering sitagliptin in patients with type 2 diabetes mellitus

Abstract

We present the results of an independent, drug company-unsupported follow-up of patients with type 2 diabetes mellitus (T2DM) treated with the dipeptidyl peptidase 4 inhibitor sitagliptin.

Keywords

• sitagliptin
• type 2 diabetes mellitus
• side effects